Sun Huanli, Zhong Zhiyuan
Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, PR China.
College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, PR China.
Biomacromolecules. 2025 Jan 13;26(1):33-42. doi: 10.1021/acs.biomac.4c01257. Epub 2024 Dec 12.
Bioresponsive polymeric nanoparticles (NPs) that are capable of delivering and releasing therapeutics and biotherapeutics to target sites have attracted vivid interest in cancer therapy and immunotherapy. In contrast to enthusiastic evolution in the academic world, the clinical translation of these smart systems is scarce, partly due to concerns about safety, stability, complexity, and scalability. The moderate targetability, responsivity, and benefits are other concerns. In the past 17 years, we have devoted ourselves to exploring elegant strategies to address the above basic and translational problems by introducing diverse functional groups and/or targeting ligands to safe biomedical materials, such as biodegradable polymers and water-soluble polymers. This minimal modification is critical for further clinical translation. We have tailor-made various bioresponsive NPs including shell-sheddable and/or acid-sensitive biodegradable NPs, disulfide-cross-linked biodegradable micelles and polymersomes, and blood-brain barrier (BBB)-permeable NPs, to target different tumors. This perspective provides an overview of our work path toward targeted nanomedicines and personalized vaccines, which might inspire clinical translation and future research on cancer therapy.
能够将治疗药物和生物治疗药物递送至靶位点并释放的生物响应性聚合物纳米颗粒(NPs)在癌症治疗和免疫治疗中引起了广泛关注。与学术界的蓬勃发展形成对比的是,这些智能系统的临床转化却很少,部分原因是对安全性、稳定性、复杂性和可扩展性的担忧。适度的靶向性、响应性和益处也是其他需要考虑的问题。在过去的17年里,我们致力于探索巧妙的策略,通过将各种官能团和/或靶向配体引入安全的生物医学材料,如可生物降解聚合物和水溶性聚合物,来解决上述基础和转化问题。这种最小化修饰对于进一步的临床转化至关重要。我们定制了各种生物响应性NPs,包括可脱壳和/或酸敏性可生物降解NPs、二硫键交联的可生物降解胶束和聚合物囊泡,以及可透过血脑屏障(BBB)的NPs,以靶向不同的肿瘤。本综述概述了我们在靶向纳米药物和个性化疫苗方面的工作路径,这可能会激发癌症治疗的临床转化和未来研究。